Clinical Trial

A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
The study was discontinued due to a strategic business/portfolio decision by the sponsor and was not related to any medical or safety issue.
Summary
The main purpose of this study is to evaluate the efficacy of crovalimab compared with placebo as an add-on therapy to vitamin K antagonist (VKA) in participants with APS.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-09-11; most recent amendment 2026-02-26.
Status change: Not Yet Recruiting → Withdrawn 2026-02-26
Trial Details
NCT Number NCT07172022
Lead Sponsor Hoffmann-La Roche
Conditions Antiphospholipid Syndrome
Start Date 2026-03-16
Primary Completion 2030-03-11 (estimated)
Study Completion 2030-12-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-02